- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05806073
Elective vs Therapeutic Neck Dissection in Treatment of Patients With Clinical T1/2N1M0 Oral Squamous Cell Carcinoma
Cervical lymph node metastasis is the most important prognostic factor of oral squamous cell carcinoma (OSCC). Therapeutic neck dissection (I-V region) has always been regarded as the standard scheme of neck surgery for patients with cN+ OSCC and however, it has brought obvious side effects, which seriously affects the postoperative quality of life of patients. In addition, excessive neck lymph node dissection will also affect the local immune function of patients to some extent and reduce the body's response to immunotherapy. Lymph node metastasis of primary oral squamous cell carcinoma follows certain rules. Most of the metastatic areas are I-II, and low-level metastasis is very rare. Therefore, more than 90% of patients with cN+ oral squamous cell carcinoma who have undergone Therapeutic neck dissection may have suffered from "excessive dissection of area of IV and V".
Both the long-term clinical experience of surgeons and a large number of recent retrospective studies show that elective neck dissection (I-III region) is safe enough for patients with oral squamous cell carcinoma of cN1 and part of cN2.There is clearly a need therefore for a large randomized trial that will resolve the issue either way once and for all.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Hong Zhen
- Phone Number: 5576 +86-(021)23271699
- Email: hannannan111@126.com
Study Contact Backup
- Name: Min Ruan
- Phone Number: +86-18717893527
- Email: doctorruanmin@sjtu.edu.cn
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Histologically proven T1 or T2 N1 M0( AJCC 8th) squamous call carcinoma of tongue(except base of the tongue ), buccal mucosa, upper and lower gums, hard palate and floor of mouth;
- No history of chemotherapy, radiotherapy or targeted therapy,for any reason before
- No history of a prior malignancy in head and neck region
- No history of a prior malignancy outside head and neck region in the preceding 5 years
- Eastern Cooperative Oncology Group Performance score (ECOG PS) is 0 or 1;
- Participants will be reliable for follow-up
- Understanding the protocol and is able to give informed consent
Exclusion Criteria:
- failed to obtain the signed written informed consent;
- definite distant metastasis or other malignant tumor;
- Previous surgical operations for primary tumors or lymph nodes in the head and neck (except biopsy);
- previously received radiotherapy for primary tumors or lymph nodes;
- previously received anti-tumor biological targeted therapy;
- Chemotherapy or immunotherapy has been applied to the primary tumor in the past;
- Patients with any malignant tumor in the past 5 years (except the cured basal cell carcinoma of the skin or cervical carcinoma in situ);
- Any unstable systemic disease (including active infection, uncontrolled hypertension, unstable angina pectoris, angina pectoris that started in the last 3 months, congestive heart failure, myocardial infarction that occurred in the first 12 months, serious arrhythmia requiring medical treatment, liver, kidney or metabolic diseases);
- known human immunodeficiency virus (HIV) infection;
- chronic diseases requiring immune preparations or hormone treatment;
- pregnant or lactating women;
- drug/alcohol abuse, or suffering from psychological or mental diseases that may interfere with research compliance;
- Epilepsy patients who need medical treatment (such as steroids or antiepileptic drugs);
- participated in other clinical trials in the past 30 days;
- cases that the researcher thinks are not suitable for joining the group.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Elective neck dissection
patient underwent elective neck dissection(level I-III) as initial treatment, along with the excision of the primary tumor
|
patient underwent elective neck dissection(level I-III) as initial treatment, along with the excision of the primary tumor
|
Experimental: Therapeutic neck dissection
Patient underwent therapeutic neck dissection(level I-V) as initial treatment, along with the excision of the primary tumor
|
patient underwent Therapeutic neck dissection(level I-V) as initial treatment, along with the excision of the primary tumor
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recurrence rate of neck
Time Frame: up to 2 year
|
From date of randomization until the date of metastasis of ipsilateral or contralateral cervical lymph nodes
|
up to 2 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival
Time Frame: up to 2 year
|
From date of randomization until the date of death from any cause
|
up to 2 year
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SH9H-2022-T349-2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Oral Squamous Cell Carcinoma
-
National Cancer Institute (NCI)CompletedRecurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Recurrent Lip and Oral Cavity Squamous Cell Carcinoma | Recurrent Laryngeal Verrucous Carcinoma | Recurrent Oral Cavity Verrucous Carcinoma | Tongue... and other conditionsUnited States
-
Emory UniversitySynta Pharmaceuticals Corp.TerminatedStage IVA Oral Cavity Squamous Cell Carcinoma | Stage IVA Laryngeal Squamous Cell Carcinoma | Stage IVA Oropharyngeal Squamous Cell Carcinoma | Stage I Hypopharyngeal Squamous Cell Carcinoma | Stage I Laryngeal Squamous Cell Carcinoma | Stage I Oropharyngeal Squamous Cell Carcinoma | Stage II... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Bristol-Myers SquibbCompletedStage IVA Oral Cavity Squamous Cell Carcinoma | Stage IV Hypopharyngeal Squamous Cell Carcinoma | Stage IVA Laryngeal Squamous Cell Carcinoma | Stage IVA Oropharyngeal Squamous Cell Carcinoma | Stage IVB Laryngeal Squamous Cell Carcinoma | Stage IVB Oropharyngeal Squamous Cell Carcinoma | Stage... and other conditionsUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedHuman Papillomavirus Infection | Stage IVA Oral Cavity Squamous Cell Carcinoma | Stage IVA Oropharyngeal Squamous Cell Carcinoma | Stage IVB Oropharyngeal Squamous Cell Carcinoma | Stage IVC Oropharyngeal Squamous Cell Carcinoma | Stage I Oropharyngeal Squamous Cell Carcinoma | Stage II Oropharyngeal... and other conditionsUnited States
-
Shanghai Jiao Tong University School of MedicineCompletedStage IVA Oral Cavity Squamous Cell Carcinoma | Stage III Oral Cavity Squamous Cell CarcinomaChina
-
National Cancer Institute (NCI)TerminatedRecurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Stage IVA Oral Cavity Squamous Cell Carcinoma | Stage IVA Laryngeal Squamous Cell Carcinoma | Stage... and other conditionsCanada, United States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedRecurrent Head and Neck Squamous Cell Carcinoma | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Caregiver | Salivary Gland Squamous Cell Carcinoma | Malignant Head and Neck Neoplasm | Recurrent Lip and Oral Cavity Squamous Cell Carcinoma | Stage... and other conditionsUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)TerminatedStage I Oral Cavity Squamous Cell Carcinoma | Stage II Oral Cavity Squamous Cell CarcinomaUnited States
-
NRG OncologyNational Cancer Institute (NCI)RecruitingOral Cavity Squamous Cell Carcinoma | Stage I Lip and Oral Cavity Cancer AJCC v8 | Stage II Lip and Oral Cavity Cancer AJCC v8 | Buccal Mucosa Squamous Cell Carcinoma | Floor of Mouth Squamous Cell Carcinoma | Gingival Squamous Cell Carcinoma | Hard Palate Squamous Cell Carcinoma | Lip Squamous Cell... and other conditionsUnited States, Canada
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruitingOropharyngeal Squamous Cell Carcinoma | Oral Squamous Cell Carcinoma | Oral Cavity Squamous Cell CarcinomaChina
Clinical Trials on Therapeutic neck dissection
-
Tata Memorial HospitalUnknown
-
Guang-Yan YuNational Natural Science Foundation of China; Peking University School of StomatologyRecruiting
-
Fondazione Policlinico Universitario Agostino Gemelli...CompletedPatients With Papillary Thyroid Cancer and N1b StatusItaly
-
Cancer Institute and Hospital, Chinese Academy...Jilin Provincial Tumor Hospital; Hebei Medical University Fourth Hospital; Liaoning... and other collaboratorsUnknownLaryngeal Neoplasms | Malignant Neoplasm of Supraglottis Primary | Neck DislocationChina
-
Centro de Excelencia en Enfermedades de Cabeza...Hospital San Vicente Fundación; Hospital Alma Mater de Antioquia; Clinica Las...Recruiting
-
Sun Yat-sen UniversityFirst Affiliated Hospital, Sun Yat-Sen University; Sun Yat-Sen Memorial Hospital...UnknownOral Squamous Cell CarcinomaChina
-
Centre Hospitalier Universitaire de NīmesCompleted
-
Rigshospitalet, DenmarkRecruitingHead and Neck Squamous Cell Carcinoma | PET/CTDenmark
-
Yonsei UniversityUnknownHead and Neck NeoplasmsKorea, Republic of